Comparing BioDelivery Sciences International (BDSI) & CoLucid Pharmaceuticals (CLCD)
BioDelivery Sciences International (NASDAQ: BDSI) and CoLucid Pharmaceuticals (NASDAQ:CLCD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.
This table compares BioDelivery Sciences International and CoLucid Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioDelivery Sciences International||10.40%||33.83%||6.43%|
This table compares BioDelivery Sciences International and CoLucid Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|BioDelivery Sciences International||$15.55 million||8.44||-$67.13 million||($0.19)||-12.37|
CoLucid Pharmaceuticals has higher revenue, but lower earnings than BioDelivery Sciences International. CoLucid Pharmaceuticals is trading at a lower price-to-earnings ratio than BioDelivery Sciences International, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
43.9% of BioDelivery Sciences International shares are owned by institutional investors. Comparatively, 64.2% of CoLucid Pharmaceuticals shares are owned by institutional investors. 9.0% of BioDelivery Sciences International shares are owned by company insiders. Comparatively, 13.7% of CoLucid Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and target prices for BioDelivery Sciences International and CoLucid Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioDelivery Sciences International||0||1||5||0||2.83|
BioDelivery Sciences International presently has a consensus price target of $4.50, suggesting a potential upside of 91.49%. CoLucid Pharmaceuticals has a consensus price target of $47.83, suggesting a potential upside of 2.80%. Given BioDelivery Sciences International’s stronger consensus rating and higher possible upside, equities analysts plainly believe BioDelivery Sciences International is more favorable than CoLucid Pharmaceuticals.
BioDelivery Sciences International beats CoLucid Pharmaceuticals on 8 of the 10 factors compared between the two stocks.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.
CoLucid Pharmaceuticals Company Profile
CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.
Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.